Roles of mesangial C3 and C1q deposition in the clinical manifestations and prognosis of IgAN
- PMID: 37235963
- DOI: 10.1016/j.intimp.2023.110354
Roles of mesangial C3 and C1q deposition in the clinical manifestations and prognosis of IgAN
Abstract
Background and aim: Immunoglobulin A nephropathy (IgAN) is regarded as the most common type of glomerulonephritis around the world and has the potential to result in renal failure. Complement activation has been addressed by a great body of evidence in the pathogenesis of IgAN. We aimed to evaluate the predictive value of C3 and C1q deposition for disease progression in IgAN patients in this retrospective study.
Methods: We recruited 1191 biopsy-diagnosed IgAN patients, and they were divided into different groups according to their glomerular immunofluorescence examination of renal biopsy tissues: 1) C3 deposits ≥ 2 + group (N = 518) and C3 deposits < 2 + group (N = 673). 2) C1q deposit-positive group (N = 109) and C1q deposit-negative group (N = 1082). The renal outcomes were end-stage renal disease (ESRD) and/or an estimated glomerular filtration rate (eGFR) decrease greater than 50% from the baseline value. Kaplan-Meier analyses were performed to evaluate renal survival. Univariate and multivariate Cox proportional hazard regression models were used to evaluate the effect of C3 and C1q deposition on renal outcome in IgAN patients. In addition, we compared the predictive value of mesangial C3 and C1q deposition in IgAN patients.
Results: The median follow-up period was 53 months (interquartile range 36-75 months). During follow-up, 7% (84) of patients progressed to ESRD, and 9% (111) of patients had an eGFR decline ≥ 50%. IgAN patients complicated with C3 deposits ≥ 2 + were associated with more severe renal dysfunction and pathologic lesions at the time of renal biopsy. The crude incidence rates for the endpoint were 12.5% (84 out of 673) and 17.2% (89 out of 518) in the C3 < 2 + and C3 ≥ 2 + groups, respectively (P = 0.022). Of C1q deposit-positive and C1q deposit-negative patients, 22.9% (25 out of 109) and 13.7% (148 out of 1082) reached the composite endpoint, respectively (P = 0.009). Adding C3 deposition to clinical and pathologic models had better predictability of renal disease progression than C1q.
Conclusion: Glomerular C3 and C1q deposits affected the clinicopathologic features of IgAN patients and emerged as independent predictors and risk factors for renal outcomes. In particular, the predictive ability of C3 was slightly better than that of C1q.
Keywords: C1q deposition; C3 deposition; Immunoglobulin A nephropathy; Renal outcomes.
Copyright © 2023 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Clinical and prognostic significance of C1q deposition in IgAN patients-a retrospective study.Int Immunopharmacol. 2020 Nov;88:106896. doi: 10.1016/j.intimp.2020.106896. Epub 2020 Oct 14. Int Immunopharmacol. 2020. PMID: 33182045
-
Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study.BMC Nephrol. 2021 Jan 29;22(1):43. doi: 10.1186/s12882-021-02237-w. BMC Nephrol. 2021. PMID: 33514328 Free PMC article.
-
A multicenter, prospective, observational study to determine association of mesangial C1q deposition with renal outcomes in IgA nephropathy.Sci Rep. 2021 Mar 9;11(1):5467. doi: 10.1038/s41598-021-84715-7. Sci Rep. 2021. PMID: 33750830 Free PMC article. Clinical Trial.
-
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.Nephrology (Carlton). 2016 Jul;21 Suppl 1:48-52. doi: 10.1111/nep.12775. Nephrology (Carlton). 2016. PMID: 26971743 Review.
-
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy.Drugs. 2023 Nov;83(16):1475-1499. doi: 10.1007/s40265-023-01940-2. Epub 2023 Sep 25. Drugs. 2023. PMID: 37747686 Free PMC article. Review.
Cited by
-
Clinical significance of glomerular IgM deposit in IgA nephropathy: a 5-year follow-up study.Ren Fail. 2024 Dec;46(2):2386146. doi: 10.1080/0886022X.2024.2386146. Epub 2024 Aug 1. Ren Fail. 2024. PMID: 39091091 Free PMC article.
-
Relationship between IgM deposition in the mesangial region and the prognosis of IgA nephropathy: a single-centre retrospective study.BMC Nephrol. 2024 Nov 30;25(1):438. doi: 10.1186/s12882-024-03880-9. BMC Nephrol. 2024. PMID: 39614180 Free PMC article.
-
Detection of N‑glycoprotein associated with IgA nephropathy in urine as a potential diagnostic biomarker using glycosylated proteomic analysis.Exp Ther Med. 2023 Aug 23;26(4):478. doi: 10.3892/etm.2023.12177. eCollection 2023 Oct. Exp Ther Med. 2023. PMID: 37753295 Free PMC article.
-
The prognostic role of activation of the complement pathways in the progression of advanced IgA nephropathy to end-stage renal disease.BMC Nephrol. 2024 Oct 30;25(1):387. doi: 10.1186/s12882-024-03832-3. BMC Nephrol. 2024. PMID: 39478440 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous